Investing.com - Affimed (NASDAQ:AFMD) NV reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Affimed NV announced earnings per share of €-0.110 on revenue of €14.9M. Analysts polled by Investing.com anticipated EPS of €-0.170 on revenue of €6.4M.
Affimed NV shares are down 63% from the beginning of the year, still down 72.24% from its 52 week high of €7.35 set on November 22, 2021.
Affimed NV follows other major Healthcare sector earnings this month
Affimed NV's report follows an earnings beat by J&J on October 18, who reported EPS of €2.55 on revenue of €23.79B, compared to forecasts EPS of €2.48 on revenue of €23.36B.
Eli Lilly had beat expectations on November 1 with third quarter EPS of €1.98 on revenue of €6.94B, compared to forecast for EPS of €1.91 on revenue of €6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar